StreetInsider.com News Articles

Form 4 REPLIGEN CORP For: Jul 16 Filed by: Garland Jason K

Fri, 17 Jul 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260717/26784828.html

Form 4 REPLIGEN CORP For: Jul 16 Filed by: Garland Jason K

Fri, 17 Jul 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260717/26784828.html

Form 144 REPLIGEN CORP Filed by: Garland Jason K

Thu, 16 Jul 2026 13:45:00 -0400

si-local-file:///var/storage/secattach/20260716/26778966.html

Form 144 REPLIGEN CORP Filed by: Garland Jason K

Thu, 16 Jul 2026 13:45:00 -0400

si-local-file:///var/storage/secattach/20260716/26778966.html

Repligen to Report Second Quarter 2026 Financial Results

Wed, 15 Jul 2026 07:30:00 -0400

WALTHAM, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that the Company will report its second quarter 2026 financial results on Tuesday, July 28, 2026. The Company will issue a press release before the market opens and will host a conference call at 8:00 a.m. ET to discuss business updates and financial results for the three-month reporting period ended June 30, 2026.

The conference call will be accessible by dialing toll-free (833) 461-5787 for domestic callers and (585) 542-9983 for international callers. The meeting ID is: 768981187. In addition, a webcast

Repligen to Report Second Quarter 2026 Financial Results

Wed, 15 Jul 2026 07:30:00 -0400

The conference call will be accessible by dialing toll-free (833) 461-5787 for domestic callers and (585) 542-9983 for international callers. The meeting ID is: 768981187. In addition, a webcast

Repligen to Report Second Quarter 2026 Financial Results

Wed, 15 Jul 2026 07:30:00 -0400

The conference call will be accessible by dialing toll-free (833) 461-5787 for domestic callers and (585) 542-9983 for international callers. The meeting ID is: 768981187. In addition, a webcast

Repligen to Report Second Quarter 2026 Financial Results

Wed, 15 Jul 2026 07:30:00 -0400

The conference call will be accessible by dialing toll-free (833) 461-5787 for domestic callers and (585) 542-9983 for international callers. The meeting ID is: 768981187. In addition, a webcast

Benchmark Upgrades Repligen (RGEN) to Buy

Tue, 07 Jul 2026 06:26:32 -0400

Benchmark analyst Robert Wasserman upgraded Repligen (NASDAQ: RGEN) from Hold to Buy with a price target of $185.00.

For an analyst ratings summary and ratings history on Repligen click here. For more ratings news on Repligen click here.

Shares of Repligen closed at $141.46 yesterday.

Form 4 REPLIGEN CORP For: Jun 25 Filed by: Garland Jason K

Fri, 26 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260626/26698667.html

Form 4 REPLIGEN CORP For: Jun 25 Filed by: Garland Jason K

Fri, 26 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260626/26698667.html

Form 144 REPLIGEN CORP Filed by: Garland Jason K

Thu, 25 Jun 2026 13:55:00 -0400

si-local-file:///var/storage/secattach/20260625/26691269.html

Form 144 REPLIGEN CORP Filed by: Garland Jason K

Thu, 25 Jun 2026 13:55:00 -0400

si-local-file:///var/storage/secattach/20260625/26691269.html

Repligen (RGEN) PT Lowered to $150 at HSBC

Wed, 03 Jun 2026 05:12:23 -0400

HSBC analyst Sidharth Sahoo lowered the price target on Repligen (NASDAQ: RGEN) to $150.00 (from $170.00) while maintaining a Buy rating.

Wolfe Research Assumes Repligen (RGEN) at Outperform

Mon, 01 Jun 2026 16:29:51 -0400

(Updated - June 1, 2026 4:29 PM EDT)

Wolfe Research analyst Mike Polark assumes coverage on Repligen (NASDAQ: RGEN) with a Outperform rating and a price target of $145.00.

The analyst comments "We rate RGEN shares Outperform and have a $145 target price. This represents 60 times our 2027 EPS. Yes we know we just wrote that. Context? (1) RGEN’s absolute average P/E back 10 years closer to 75x; (2) RGEN’s average P/E premium to the Tools sector back 10 years is about 3x so with sector at 20x holding this relationship constant gets you 60 here; (3) does RGEN work in

Wolfe Research Assumes Repligen (RGEN) at Outperform

Mon, 01 Jun 2026 16:29:51 -0400

(Updated - June 1, 2026 4:29 PM EDT)

Wolfe Research analyst Mike Polark assumes coverage on Repligen (NASDAQ: RGEN) with a Outperform rating and a price target of $145.00.

William Blair Updates Analyst Conviction List for June 2026, 6 Adds & 5 Removals

Mon, 01 Jun 2026 07:26:29 -0400